Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12488367 | 0.86 | CFTR (0.43) | CFTRGAAABL1MEN1KMT2A | |
| SCHEMBL2849661 | 0.85 | CFTR (0.45) | CFTRGAAABL1MEN1KMT2A | |
| SCHEMBL14590043 | 0.85 | GAA (0.47) | GAAABL1MEN1KMT2ALMNA | |
| SCHEMBL30280800 | 0.83 | CFTR (0.46) | CFTRGAAKMT2ALMNANR4A2 | |
| SCHEMBL7863946 | 0.83 | GAA (0.50) | GAAABL1MEN1KMT2ALMNA | |
| SCHEMBL25455691 | 0.83 | CFTR (0.46) | CFTRGAAABL1LMNANR4A2 | |
| SCHEMBL1920431 | 0.83 | CFTR (0.46) | CFTRGAAKMT2ALMNANR4A2 | |
| SCHEMBL7948445 | 0.82 | NR4A2 (0.46) | CFTRGAAABL1MEN1KMT2A | |
| SCHEMBL7082612 | 0.81 | GAA (0.46) | CFTRGAAABL1MEN1KMT2A | |
| SCHEMBL8331820 | 0.81 | GAA (0.53) | CFTRGAAABL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | CFTR 3347/4885GAA 1648/4885ABL1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.